Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by RobertoLon Feb 28, 2023 12:42pm
94 Views
Post# 35310056

Annual General and Special Meeting Tuesday February 28,2023

Annual General and Special Meeting Tuesday February 28,2023
This information circular (the “Information Circular”) accompanies the notice of annual general and
special meeting of shareholders (the “Notice”) of RepliCel Life Sciences Inc. (the “Company”) and is
furnished to shareholders (each, a “Shareholder”) holding common shares (each, a “Share”) in the
capital of the Company in connection with the solicitation by the management of the Company of proxies
to be voted at theannual general and special meeting (the “Meeting”) of the Shareholders to be held at
2:00 p.m.(5:00 p.m est) on Tuesday, February 28, 2023 at the offices of Clark Wilson LLP, Suite 900, 885 West Georgia
Street, Vancouver, BC V6C 3H1 and via ZOOM at https://us02web.zoom.us/j/81899092491 Meeting ID:
818 9909 2491, or at any adjournment or postponement thereof. All references to Shareholders in this
Information Circular are to registered Shareholders unless specifically stated otherwise
<< Previous
Bullboard Posts
Next >>